More recent data from Fruscione et al. [11] implicate a sodium channel inhibitory role for PRRT2, which becomes less inhibited in disease-associated PRRT2 mutations, and which offers an explanation for the sensitivity of both seizures and dyskinesias to sodium channel–blocking agents like carbamazepine. The gene discussed is PRRT2; the disease is drug-induced dyskinesia.